Eicosapentaenoic acid ameliorates non-alcoholic steatohepatitis in a novel mouse model using melanocortin 4 receptor-deficient mice

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Konuma, Kuniha ^a   Itoh, Michiko ^a   Suganami, Takayoshi ^a,b   Kanai, Sayaka ^a   Nakagawa, Nobutaka ^a   Sakai, Takeru ^a   Kawano, Hiroyuki ^c   Hara, Mitsuko ^d   Kojima, Soichi ^d   Izumi, Yuichi ^a   Ogawa, Yoshihiro ^a,b  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c Pharmaceutical Research Center   (Japan)

^d RIKEN   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ICOSAPENTAENOIC ACID; KALLIKREIN; MELANOCORTIN 4 RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; ADIPOCYTOKINE; ADIPOQ PROTEIN, MOUSE; MC4R PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFIBROTIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG ACTIVITY; DRUG MECHANISM; ENZYME ACTIVATION; LIPID STORAGE; LIVER CELL DAMAGE; LIVER FIBROSIS; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN BLOOD LEVEL; ANIMAL; BLOOD; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; KNOCKOUT MOUSE; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY;

MUS; RODENTIA;

ADIPOKINES; ADIPONECTIN; ANIMALS; DISEASE MODELS, ANIMAL; EICOSAPENTAENOIC ACID; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; MICE; MICE, KNOCKOUT; NON-ALCOHOLIC FATTY LIVER DISEASE; RECEPTOR, MELANOCORTIN, TYPE 4;

EID: 84926351030     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0121528     Document Type: Article

References (54)

1. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99-S112. PMID: 16447287
2. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-845. PMID: 9547102
3. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004; 114: 147-152. PMID: 15254578
4. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010; 52: 774-788. doi: 10.1002/hep.23719 PMID: 20683968
5. Itoh M, Suganami T, Nakagawa N, Tanaka M, Yamamoto Y, Kamei Y, et al. Melanocortin 4 receptor-deficient mice as a novel mouse model of nonalcoholic steatohepatitis. Am J Pathol 2011; 179: 2454-2463. doi: 10.1016/j.ajpath.2011.07.014 PMID: 21906580
6. Balthasar N, Dalgaard LT, Lee CE, Yu J, Funahashi H, Williams T, et al. Divergence of melanocortin pathways in the control of food intake and energy expenditure. Cell 2005; 123: 493-505. PMID: 16269339
7. Gautron L, Lee C, Funahashi H, Friedman J, Lee S, Elmquist JK. Melanocortin-4 receptor expression in a vago-vagal circuitry involved in postprandial functions. J Comp Neurol 2010; 518: 6-24. doi: 10.1002/cne.22221 PMID: 19882715
8. Itoh M, Kato H, Suganami T, Konuma K, Marumoto Y, Terai S, et al. Hepatic crown-like structure: a unique histological feature in non-alcoholic steatohepatitis in mice and humans. PloS one 2013; 8: e82163. doi: 10.1371/journal.pone.0082163 PMID: 24349208
9. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-867. PMID: 17167474
10. Jump DB. The biochemistry of n-3 polyunsaturated fatty acids. J Biol Chem 2002; 277: 8755-8758. PMID: 11748246
11. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002; 106: 2747-2757. PMID: 12438303
12. Larter CZ, Yeh MM, Cheng J, Williams J, Brown S, dela Pena A, et al. Activation of peroxisome proliferator-activated receptor α by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation. J Gastroenterol Hepatol 2008; 23: 267-275. PMID: 17868330
13. Ishii H, Horie Y, Ohshima S, Anezaki Y, Kinoshita N, Dohmen T, et al. Eicosapentaenoic acid ameliorates steatohepatitis and hepatocellular carcinoma in hepatocyte-specific Pten-deficient mice. J Hepatol 2009; 50: 562-571. doi: 10.1016/j.jhep.2008.10.031 PMID: 19162361
14. Kajikawa S, Harada T, Kawashima A, Imada K, Mizuguchi K. Highly purified eicosapentaenoic acid ethyl ester prevents development of steatosis and hepatic fibrosis in rats. Dig Dis Sci 2010; 55: 631-641. doi: 10.1007/s10620-009-1020-0 PMID: 19856102
15. Kajikawa S, Imada K, Takeuchi T, Shimizu Y, Kawashima A, Harada T, et al. Eicosapentaenoic acid attenuates progression of hepatic fibrosis with inhibition of reactive oxygen species production in rats fed methionine- and choline-deficient diet. Dig Dis Sci 2011; 56: 1065-1074. doi: 10.1007/s10620-010-1400-5 PMID: 20848203
16. Depner CM, Philbrick KA, Jump DB. Docosahexaenoic acid attenuates hepatic inflammation, oxidative stress, and fibrosis without decreasing hepatosteatosis in a Ldlr(-/-) mouse model of western diet-induced nonalcoholic steatohepatitis. J Nutr 2013; 143: 315-323. doi: 10.3945/jn.112.171322 PMID: 23303872
17. Svegliati-Baroni G, Candelaresi C, Saccomanno S, Ferretti G, Bachetti T, Marzione M, et al. A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-α and n-3 polyunsaturated fatty acid treatment on liver injury. Am J Pathol 2006; 169: 846-860. PMID: 16936261
18. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142: 1592-1609. doi: 10.1053/j.gastro.2012.04.001 PMID: 22656328
19. Capanni M, Calella F, Biagini MR, Genise S, Raimondi L, Bedogni G, et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther 2006; 23: 1143-1151. PMID: 16611275
20. Di Minno MN, Russolillo A, Lupoli R, Ambrosino P, Di Minno A, Tarantino G. Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. World J Gastroenterol 2012; 18: 5839-5847. doi: 10.3748/wjg.v18.i41.5839 PMID: 23139599
21. Tanaka N, Sano K, Horiuchi A, Tanaka E, Kiyosawa K, Aoyama T. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol 2008; 42: 413-418. doi: 10.1097/MCG.0b013e31815591aa PMID: 18277895
22. Sanyal AJ, Abdelmalek MF, Suzuki A, Cummings OW, Chojkier M; EPA-A Study Group. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology 2014; 147: 377-384 e371. doi: 10.1053/j.gastro.2014.04.046 PMID: 24818764
23. Scorletti E, Bhatia L, McCormick KG, Clough GF, Nash K, Hadson L, et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in non-alcoholic fatty liver disease: Results from the ∗WELCOME study. Hepatology 2014 Jul 4. doi: 10.1002/hep.27289
24. Dasarathy S, Dasarathy J, Khiyami A, Yerian L, Hawkins C, Sargent R, et al. Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol 2015; 49: 137-144. doi: 10.1097/MCG.0000000000000099 PMID: 24583757
25. Argo CK, Patrie JT, Lackner C, Henry TD, deLange EE, Weltman AL, et al. Effects of n-3 fish oil on metabolic and histological parameters in NASH: A double-blind, randomized, placebo-controlled trial. J Hepatol 2015; 62: 190-197. doi: 10.1016/j.jhep.2014.08.036 PMID: 25195547
26. Itoh M, Suganami T, Satoh N, Tanimoto-Koyama K, Yuan X, Tanaka M, et al. Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects. Arterioscler Thromb Vasc Biol 2007; 27: 1918-1925. PMID: 17569885
27. Sato A, Kawano H, Notsu T, Ohta M, Nakakuki M, Mizuguchi K, et al. Antiobesity effect of eicosapentaenoic acid in high-fat/high-sucrose diet-induced obesity: importance of hepatic lipogenesis. Diabetes 2010; 59: 2495-2504. doi: 10.2337/db09-1554 PMID: 20682690
28. Leclercq IA, Farrell GC, Schriemer R, Robertson GR. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 2002; 37: 206-213. PMID: 12127425
29. Kitagawa K, Wada T, Furuichi K, Hashimoto H, Ishiwata Y, Asano M, et al. Blockade of CCR2 ameliorates progressive fibrosis in kidney. Am J Pathol 2004; 165: 237-246. PMID: 15215179
30. Hara M, Kirita A, Kondo W, Matsuura T, Nagatsuma K, Dohmae N, et al. LAP degradation product reflects plasma kallikrein-dependent TGF-β activation in patients with hepatic fibrosis. SpringerPlus 2014; 3: 221. doi: 10.1186/2193-1801-3-221 PMID: 24877031
31. Juluri R, Vuppalanchi R, Olson J, Unalp A, Van Natta ML, Cummings OW, et al. Generalizability of the Nonalcoholic Steatohepatitis Clinical Research Network Histologic Scoring System for Nonalcoholic Fatty Liver Disease. J Clin Gastroenterol 2010; 45: 55-58.
32. Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 2009; 50: 957-969. doi: 10.1002/hep.23046 PMID: 19585655
33. Ioannou GN, Haigh WG, Thorning D, Savard C. Hepatic cholesterol crystals and crown-like structures distinguish NASH from simple steatosis. J Lipid Res 2013; 54: 1326-1334. doi: 10.1194/jlr.M034876 PMID: 23417738
34. Akita K, Okuno M, Enya M, Imai S, Moriwaki H, Kawada N, et al. Impaired liver regeneration in mice by lipopolysaccharide via TNF-α/kallikrein-mediated activation of latent TGF-β. Gastroenterology 2002; 123: 352-364. PMID: 12105863
35. Varela-Rey M, Embade N, Ariz U, Lu SC, Mato JM, Martinez-Chantar ML. Non-alcoholic steatohepatitis and animal models: understanding the human disease. Int J Biochem Cell Biol 2009; 41: 969-976. doi: 10.1016/j.biocel.2008.10.027 PMID: 19027869
36. Larter CZ, Yeh MM, Haigh WG, Williams J, Brown S, Bell-Anderson KS, et al. Hepatic free fatty acids accumulate in experimental steatohepatitis: role of adaptive pathways. J Hepatol 2008; 48: 638-647. doi: 10.1016/j.jhep.2007.12.011 PMID: 18280001
37. Kakisaka K, Cazanave SC, Fingas CD, Guicciardi ME, Bronk SF, Werneburg NW, et al. (2012) Mechanisms of lysophosphatidylcholine-induced hepatocyte lipoapoptosis. Am J Physiol Gastrointest Liver Physiol 2012; 302: G77-84. doi: 10.1152/ajpgi.00301.2011 PMID: 21995961
38. Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003; 125: 437-443. PMID: 12891546
39. Richard D, Kefi K, Barbe U, Bausero P, Visioli F. Polyunsaturated fatty acids as antioxidants. Pharmacol Res 2008; 57: 451-455. doi: 10.1016/j.phrs.2008.05.002 PMID: 18583147
40. Cazanave SC, Gores GJ. Mechanisms and clinical implications of hepatocyte lipoapoptosis. Clin Lipidol 2010; 5: 71-85. PMID: 20543905
41. Calder PC. Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? Br J Clin Pharmacol 2013; 75: 645-662. doi: 10.1111/j.1365-2125.2012.04374.x PMID: 22765297
42. Okuno M, Akita K, Moriwaki H, Kawada N, Ikeda K, Kaneda K, et al. Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-β. Gastroenterology 2001; 120: 1784-1800. PMID: 11375959
43. Day CP. From fat to inflammation. Gastroenterology 2006; 130: 207-210. PMID: 16401483
44. Kamada Y, Matsumoto H, Tamura S, Fukushima J, Kiso S, Fukui K, et al. Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. J Hepatol 2007; 47: 556-564. PMID: 17459514
45. Asano T, Watanabe K, Kubota N, Gunji T, Omata M, Kadowaki T, et al. Adiponectin knockout mice on high fat diet develop fibrosing steatohepatitis. J Gastroenterol Hepatol 2009; 24: 1669-1676. doi: 10.1111/j.1440-1746.2009.06039.x PMID: 19788607
46. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112: 91-100. PMID: 12840063
47. Shklyaev S, Aslanidi G, Tennant M, Prima V, Kohlbrenner E, Kroutov V, et al. Sustained peripheral expression of transgene adiponectin offsets the development of diet-induced obesity in rats. Proc Natl Acad Sci U S A 2003; 100: 14217-14222. PMID: 14617771
48. Kamada Y, Tamura S, Kiso S, Matsumoto H, Saji Y, Yoshida Y, et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 2003; 125: 1796-1807. PMID: 14724832
49. Neschen S, Morino K, Rossbacher JC, Pongratz RL, Cline GW, Sono S, et al. Fish oil regulates adiponectin secretion by a peroxisome proliferator-activated receptor-γ-dependent mechanism in mice. Diabetes 2006; 55: 924-928. PMID: 16567512
50. Flachs P, Mohamed-Ali V, Horakova O, Rossmeisl M, Hosseinzadeh-Attar MJ, Hensler M, et al. Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed a high-fat diet. Diabetologia 2006; 49: 394-397. PMID: 16397791
51. Aleffi S, Petrai I, Bertolani C, Parola M, Colombatto S, Novo E, et al. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology 2005; 42: 1339-1348. PMID: 16317688
52. Saxena NK, Ikeda K, Rockey DC, Friedman SL, Anania FA. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology 2002; 35: 762-771. PMID: 11915021
53. Wang D, Wei Y, Pagliassotti MJ. Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis. Endocrinology 2006; 157: 943-951.
54. Savard C, Tartaglione EV, Kuver R, Haigh WG, Farrell GC, Subramanian S, et al. Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis. Hepatology 2013; 57: 81-92. doi: 10.1002/hep.25789 PMID: 22508243